丙型肝炎治疗与肝硬化患者肝细胞癌出现的时间关联:未定性结节的相关性
一项回顾性多中心研究纳入1123例接受直接抗病毒药物治疗的肝硬化患者,95.2%获得持续病毒学应答,中位随访19.6个月,72例发生肝细胞癌,发生率为3.73例/100人年(95%CI 2.96-4.70),基线存在未定性结节者相对风险为2.83(95%CI 1.55-5.16)。
要点
- 直接抗病毒药物治疗肝硬化患者后肝细胞癌发生率为3.73例/100人年(95%CI 2.96-4.70)。
- 基线存在未定性结节者肝细胞癌相对风险为2.83(95%CI 1.55-5.16)。
- 干扰素-free治疗与肝细胞癌出现存在明确时间关联,机制需进一步研究。
核心结论
- 数据揭示了干扰素-free治疗与肝细胞癌之间明确的时间关联。
- 短期肝细胞癌风险增加的机制需要进一步研究。
研究设计与样本
- 回顾性多中心研究,纳入截至2016年12月接受直接抗病毒药物治疗的肝硬化患者。
- 共纳入1123例患者,60.6%为男性,83.8%为Child-Pugh A级。
- 肝细胞癌诊断经中心统一验证,发生率以每100人年肝细胞癌例数表示。
主要发现
- 95.2%的患者获得持续病毒学应答,中位随访时间为19.6个月。
- 72例患者发生肝细胞癌,发生于开始抗病毒治疗后中位10.3个月。
- 肝细胞癌发生率为3.73例/100人年(95%CI 2.96-4.70)。
- 基线肝功能、酒精摄入和肝失代偿与肝细胞癌风险增高相关。
- 基线存在未定性结节者相对风险为2.83(95%CI 1.55-5.16),高于无未定性结节者;排除这些患者后风险仍增高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite direct-acting antivirals being highly effective at eradicating hepatitis C virus infection, their impact on the development of hepatocellular carcinoma (HCC) remains controversial. We analyzed the clinical and radiological outcome of cirrhotic patients treated with interferon-free regimens to estimate the risk of developing HCC. METHODS: This was a retrospective multicenter study focusing on cirrhotic patients treated with direct-acting antivirals until December 2016. Clinical and radiologic characteristics were collected before the start of antiviral therapy, at follow-up and at HCC development. Diagnosis of HCC was centrally validated and its incidence was expressed as HCC/100 person-years. RESULTS: A total of 1,123 patients were included (60.6% males, 83.8% Child-Pugh A) and 95.2% achieved a sustained virologic response. Median time of follow-up was 19.6 months. Seventy-two patients developed HCC within a median of 10.3 months after starting antiviral treatment. HCC incidence was 3.73 HCC/100 person-years (95% CI 2.96-4.70). Baseline liver function, alcohol intake and hepatic decompensation were associated with a higher risk of HCC. The relative risk was significantly increased in patients with non-characterized nodules at baseline 2.83 (95% CI 1.55-5.16) vs. absence of non-characterized nodules. When excluding these patients, the risk remained increased. CONCLUSION: These data expose a clear-cut time association between interferon-free treatment and HCC. The mechanisms involved in the increased risk of HCC emergence in the short term require further investigation. LAY SUMMARY: In this cohort of cirrhotic patients, interferon-free therapies achieved a high rate of sustained virologic response (>95%); however, we reported a risk of de novo hepatocellular carcinoma of 3.73 per 100 person-years and a clear-cut time association with antiviral therapy. The time association between starting direct-acting antivirals and developing hepatocellular carcinoma, together with the association with the presence of non-characterized nodules at baseline ultrasound, suggests that antiviral therapy elicits a mechanism (probably immune-related) that primes the growth and clinical recognition of hepatocellular carcinoma early during follow-up. As a result, short-term liver cancer risk is significantly increased.
引用
- Mariño Z, Darnell A, Lens S, et al. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. J Hepatol. 2019. PMID: 30684506. doi:10.1016/j.jhep.2019.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。